(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? - Wikidata - wikimedia - TriplyDB

(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?

(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?

http://www.wikidata.org/entity/Q53505313

about

PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status Target Definition in Salvage Radiotherapy for Recurrent Prostate Cancer: The Role of Advanced Molecular Imaging Updates of prostate cancer staging: Prostate-specific membrane antigen Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer.Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine.Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy Prostate-based biofluids for the detection of prostate cancer: A comparative study of the diagnostic performance of cell-sourced RNA biomarkers.68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.Impact of PET acquisition durations on image quality and lesion detectability in whole-body 68Ga-PSMA PET-MRI.Prostate Cancer Imaging with Novel PET Tracers.(68)Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging?New frontiers in prostate cancer imaging: clinical utility of prostate-specific membrane antigen positron emission tomography.Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand.Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy.The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease 68Ga-prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Prostate Cancer Imaging: A Narrative Literature Review.Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.PSMA PET and Radionuclide Therapy in Prostate Cancer.The reconstruction algorithm used for [68Ga]PSMA-HBED-CC PET/CT reconstruction significantly influences the number of detected lymph node metastases and coeliac ganglia.Metal-Based PSMA Radioligands.PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.68Ga-PSMA PET/CT imaging in recurrent prostate cancer: Where are we now?(68)Ga-HBED-CC-PSMA PET/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison.(11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (18F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks.68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.Current status of theranostics in prostate cancer.68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making.99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer.(68) Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature.Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.Clinical impact of PSMA-based 18F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy.(11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel.A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy.Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions.Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.

P2860

Q26774920-403863EF-EA34-444E-9E03-0BC3CF0B7AF7 Q28074669-5A5F5608-FEEE-4D79-84C0-4DF14F1CB454 Q28079444-06777BFF-4E86-49EB-8AE4-EF8FAB25912B Q30376901-C83FC09B-DE95-479F-B404-568F4DD47B07 Q33841484-07092D9F-5CE3-4EF0-AD8B-BF5F4D9AB6C4 Q33914844-1932422E-B3B2-4345-9743-6892C7ED60E9 Q36289592-74ED9BEC-CD9D-4602-8DE0-1D6FBF326616 Q37273884-1653A765-3DBC-41EB-9AB5-E4FD7300F77E Q37554235-CB010A85-0550-42EA-8586-04FCFF9662C0 Q37626953-1795847C-C9CC-46B3-AF07-1808D0EF88D3 Q38732369-F8E6AA66-51F1-4736-8076-EA43821FC882 Q38747415-A58A6F60-9012-476D-B8CD-452F475134EB Q38757513-8F8E844E-ED43-472E-9AC1-E69828B4A427 Q38762963-77DD68BA-1DF3-4B8A-AB80-C4501E5B98F1 Q38804450-23EFC5E5-0745-435E-8FF6-93765A153382 Q38831232-5A12AC20-165B-4281-B356-8F5D80E39BA4 Q38952552-2FE6F411-0F99-4BEA-9A23-532C029F53CF Q38966705-BBAB656A-7656-4AEB-AC08-ED4C16C085E9 Q39003089-F108F82F-F9F2-48CD-B48C-CB695ED80C87 Q39143896-30397458-B6BB-47A5-AEB0-B37C910F3D22 Q39198527-2B371383-8D9E-48C9-BE71-C4635B914D51 Q39242140-09DD8AF2-FCFE-42A3-A92B-D7A4DBAC1008 Q39276928-6F34E988-DE69-49A0-BA36-E7451C9C6535 Q39572115-B87163E5-EECD-431D-ABC2-C2AA8C34B8C1 Q39699773-97FB5053-CF8E-4201-B581-91C9406EBE6A Q39922053-E8233C88-05D6-4479-92FF-A8336F5909DC Q42379563-65A60544-4C45-4610-AD8B-9A30E2A03FBB Q43846086-FA1620BF-31DC-447B-85EA-08D3E7739E63 Q46225464-6A555D85-252A-43B7-9761-F9D1EBF8FD5A Q47107456-8A6D414D-B7A0-4E4F-9995-07F33253FD72 Q47241139-996E7ED7-8AD7-4D8E-9618-1E29B143BA08 Q47273452-0087329B-AAF8-40D5-8472-B4A3F8C52A19 Q47438555-C4285648-B5E4-4B85-AD53-4E157EEF2672 Q47693515-44537D8D-8BF2-4663-9607-E32D4BDD2358 Q47805128-A3D73F64-CC5F-44E2-B924-06E315F472B0 Q48089415-3774284D-BB49-4B19-9056-F77A3E11EEAC Q48139886-23C0D407-7C50-4AD6-A2E9-61331F9D9354 Q48177983-335AD0F2-C18B-40A5-B229-990D67194182 Q48189196-3564EB56-028C-4324-B7FB-841BD0015D4D Q48226517-1F099475-6DBB-4239-B2C9-CB310294542D

P2860

(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?

http://www.wikidata.org/entity/Q53505313

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

(68)Ga-PSMA PET/CT for restagi ...... ed with PET/CT detection rate?

@en

type

label

(68)Ga-PSMA PET/CT for restagi ...... ed with PET/CT detection rate?

@en

prefLabel

(68)Ga-PSMA PET/CT for restagi ...... ed with PET/CT detection rate?

@en

P1433

Q53505313-97B6752B-B651-4EBB-96CE-03A36F53AB73

P1476

Q53505313-A381CFA4-87FA-4041-89AF-525FBE8604FF

P2093

Q53505313-1479F653-9745-44C1-BF6D-E670AE2BD0F5

Q53505313-1C621C6B-3EA8-4C26-AA22-2D767C49B118

Q53505313-2B747F92-A43E-43BE-8763-5B4C734611EE

Q53505313-59B0B63E-DA3B-41AC-9AEA-F8C8D3768B5C

Q53505313-603F6230-C4AA-4472-8D79-7C45F62E3AE1

Q53505313-64276CD1-D6C9-43A6-A474-77D5EE1E4B05

Q53505313-810A16A6-D67F-481F-825F-F06A802974E4

Q53505313-C3D63768-F763-424F-8EF6-99EB7A4BE1AE

Q53505313-F10788A6-41F5-4601-A710-158404B04BD8

Q53505313-FDFD8324-1047-403F-A2CC-E7AF8123BC3A

P2860

Q53505313-02ABFCAF-1985-44E4-9AC0-41118F169791

Q53505313-0D34F1D4-5FB5-44FC-A101-4386B906C180

Q53505313-16D2FE2D-DBA3-4979-904C-4513D698F321

Q53505313-1B8C44F1-A9BB-4521-89AE-D935CD14C46F

Q53505313-20F147A7-2884-4FB8-B191-9DE8AC89FF67

Q53505313-28F15B17-3F9C-4E36-9419-455290FF40CE

Q53505313-52F27100-A087-4837-9513-6E379537BF04

Q53505313-63243EEE-BB0C-4C10-A024-E1E53414E247

Q53505313-67CA258F-0039-4108-B075-A8C4FDC9300C

Q53505313-6D692C01-BD95-4678-8FF0-59CD0258C3F8

P2888

Q53505313-3A59942D-96B1-4014-B086-55B13DAB65D8

P304

Q53505313-122BD93F-C417-431A-BE6A-4C68F66A63B1

P31

Q53505313-31192667-BD6B-4CD2-86AA-F539598B521B

P356

Q53505313-AFC59847-592F-4802-83B1-39430C9EA66D

P433

Q53505313-8D39D788-3360-479B-B49C-85C591011DD9

P478

Q53505313-44D201A3-4375-474C-8315-232AF59C64AB

P50

Q53505313-1508EC31-E8CE-4D88-BAFF-B39D9A839074

Q53505313-2AB2796E-97A7-4D83-B290-1FEF95BE8F8B

Q53505313-44FA522A-5AD2-4F49-84AE-34C570C389F3

P577

Q53505313-C6A73805-EFD8-4632-8605-42ED649ACAA3

P698

Q53505313-5EA46438-3F76-49CE-B1DB-5398B363623C

P356

S00259-015-3078-6

P1433

European Journal of Nuclear Medicine and Molecular Imaging

P1476

(68)Ga-PSMA PET/CT for restagi ...... ed with PET/CT detection rate?

@en

P2093

Alexander Kroiss

http://www.w3.org/2001/XMLSchema#string

Bernhard Nilica

http://www.w3.org/2001/XMLSchema#string

Christian Uprimny

http://www.w3.org/2001/XMLSchema#string

Dorota Kendler

http://www.w3.org/2001/XMLSchema#string

Irene J Virgolini

http://www.w3.org/2001/XMLSchema#string

Jasmin Bektic

http://www.w3.org/2001/XMLSchema#string

Llanos Geraldo

http://www.w3.org/2001/XMLSchema#string

Paolo Castellucci

http://www.w3.org/2001/XMLSchema#string

Peter Lukas

http://www.w3.org/2001/XMLSchema#string

Wolfgang Horninger

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Alpha emitter radium-223 and survival in metastatic prostate cancer

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.

Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.

Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy.

EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT.

P2888

s00259-015-3078-6

P304

1284-1294

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-015-3078-6

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P50

Clemens Decristoforo

P577

2015-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25975367

http://www.w3.org/2001/XMLSchema#string